Format

Send to

Choose Destination
Drug Discov Today Technol. 2007 Winter;4(2):35-41. doi: 10.1016/j.ddtec.2007.10.003.

A critical path approach to advance nanoengineered medical products.

Author information

1
Office of the Commissioner, FDA, United States. Electronic address:wendy.sanhai@hhs.fda.gov.
2
Office of Technology Transfer, National Institutes of Health, United States.
3
Alliance for NanoHealth, Houston, TX, United States.

Abstract

Still needed in nanotechnology is a product development toolkit containing both scientific and business strategies to stimulate innovation. Among the scientific tools envisioned are evaluative and predictive test methods, such as animal- and computer-based predictive models, characterization assays, toxicity tests and quantitative imaging methods to track biodistribution of nanoparticles in complex biological systems. These tools will help bridge scientific gaps and elucidate potential benefits and risks related to use of nanoengineered medical products. In addition, relevant business strategies, if carefully designed, will help overcome many of the hurdles in this field. This article describes some needed scientific/regulatory and business tools of this field and introduces one collaborative effort underway - a Critical Path Initiative [FDA's Critical Path Initiative: //www.fda.gov/oc/initiatives/criticalpath/.] - structured to bridge some existing gaps.

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center